Smith, Herman W.;

2,2-Difluoro-trans-4,5,13,14-tetrahydro-PGI.sub.1 compounds

The present invention relates to certain structural and pharmacological analogs of prostacyclin (PGI.sub.2) which are 2,2-difluoro-trans-4,5,13,14-tetradehydro-PGI.sub.1 compounds. These novel pharmacological agents are useful as smooth muscle stimulators.

• Continuous manufacture of peroxyesters Magnetic field generating assembly
• Dietary supplement for medical patients Electrical plug connection
• Device for forming underground pipelines Razor cartridge with shaving aid
• Time/temperature indicator Hand winch
• Selvedging system Video camera
• Method of ion implantation Substituted 6-hydroxy pyrimidines
• Electrical connector Molding composition
• Distributing valve Apparatus for refining molten metal
• Beverage package Orthodontic appliance
• Percolation process Scanning electron microscope
• Turn-table dual hoisting crane Power converting
• Flange for a duct Solid state storage device
• Adjustable stepladder Pipe connection
• Dual-feed single-cam compound bow High recovery sonic gas valve
• Bingo chip dispenser Memory based line-delay architecture
• Tuning fork flexural quartz resonator Swimwear vent for water skiers
• Drill tool for deep wells Variable-passband variable-phase digital filter
• Benzamidine derivatives Fungicidal N-(substituted thio)-pyridyl cyclopropane carboxamides
• Linear deposition apparatus Semiconductor pressure sensor
• Metalloproteinase inhibitor Shoulder prosthesis
• Engine starting device Isoindolenineamide dyestuffs
• Plastic pour-spout and container Work over methods and apparatus
• USB legacy support system Screw tightening power tool
• Chip resistor One-way clutch
• Multipolar switch Resource reservation
• Operating table Bottle cap jewelry
• Bypass and unloader valve Original image projecting apparatus
• High-speed cycle clock-synchrounous memory device Method of dyeing yarn
• 3-acyclic or cyclicaminomethyl-17a-lower-alkyl-17a-aza-D-homo-5-alpha-androstanes Endoscope apparatus
• Disposable double vial syringe Modular floating structure
• Valve arrangement Hepatic disturbance improver
• Steroid sulphatase inhibitors

I claim:

1. A prostacyclin analog of the formula ##STR1## wherein Y.sub.2 is --C.tbd.C--. wherein Z.sub.2 is ##STR2## wherein g is the integer zero, one, or 2; wherein M.sub.1 is ##STR3## wherein R.sub.5 is hydrogen or alkyl with one to 4 carbon atoms, inclusive;

wherein L.sub.1 is ##STR4## or a mixture of ##STR5## wherein R.sub.3 and R.sub.4 are hydrogen, methyl, or fluoro, being the same or different, with the proviso that one of R.sub.3 and R.sub.4 is fluoro only when the other is hydrogen or fluoro;

wherein R.sub.1 is hydrogen; alkyl of one to 12 carbon atoms, inclusive; cycloalkyl of 3 to 10 carbon atoms, inclusive; aralkyl of 7 to 12 carbon atoms, inclusive; phenyl; phenyl substituted with one, two or three chloro or alkyl of one to 3 carbon atoms; phenyl substituted in the para position by ##STR6## wherein R.sub.25 is methyl, phenyl, acetamidophenyl, benzamidophenyl, or --NH.sub.2 ; R.sub.26 is methyl, phenyl, --NH.sub.2, or methoxy; and R.sub.27 is hydrogen or acetamido; phenacyl, i.e., ##STR7## phenacyl substituted in the para position by chloro, bromo, phenyl, or benzamido; or a pharmacologically acceptable cation;

wherein R.sub.7 is ##STR8## wherein m is the integer one to 5, inclusive, h is the integer zero to 3, inclusive; s is the integer zero, one, 2, or 3, and T is chloro, fluoro, trifluoromethyl, alkyl of one to 3 carbon atoms, inclusive, or alkoxy of one to 3 carbon atoms, inclusive, with the proviso that not more than two T's are other than alkyl.

2. A prostacyclin analog according to claim 1, wherein Z.sub.2 is a mixture of ##STR9##

3. 2,2-Difluoro(6RS)-trans-4,5,13,14-tetradehydro-PGI.sub.1, a prostacyclin analog according to claim 2.

4. A prostacyclin analog according to claim 1, wherein Z.sub.2 is ##STR10##

5. 2,2-Difluoro-trans-4,5,13,14-tetradehydro-6.alpha.-PGI.sub.1, a prostacyclin analog according to claim 4.

6. 2,2-Difluoro-15-methyl-trans-4,5,13,14-tetradehydro-6.alpha.-PGI.sub.1, a prostacyclin analog according to claim 4.

7. 2,2-Difluoro-16,16-dimethyl-trans-4,5,13, 14-tetradehydro-6.alpha.-PGI.sub.1, a prostacyclin analog according to claim 4.

8. 2,2,16,16-Tetrafluoro-trans-4,5,13,14-tetradehydro-6.alpha.-PGI.sub.1, a prostacyclin analog according to claim 4.

9. A prostacyclin analog according to claim 1, wherein Z.sub.2 is ##STR11##

10. A prostacyclin analog according to claim 9, wherein g is zero.

11. A prostacyclin analog according to claim 10, wherein ##STR12##

12. 2,2-Difluoro-17-phenyl-18,19,20-trinor-trans-4,5,13,14-tetradehydro-6.b e ta.-PGI.sub.1, a prostacyclin analog according to claim 11.

13. A prostacyclin analog according to claim 10, wherein ##STR13##

1 4. 2,2-Difluoro-16-phenoxy-17,18,19,20-tetranor-trans-4,5,13,14-tetradehydr o-6.beta.-PGI.sub.1, a prostacyclin analog according to claim 13.

15. A prostacyclin analog according to claim 10, wherein R.sub.7 is --(CH.sub.2).sub.m --CH.sub.3 --.

16. A prostacyclin analog according to claim 15, wherein R.sub.5 is methyl.

17. 2,2-Difluro-15-methyl-trans-4,5,13,14-tetradehydro-6.beta.-PGI.sub.1, a prostacyclin analog according to claim 16.

18. A prostacyclin analog according to claim 15, wherein R.sub.5 is hydrogen.

19. A prostacyclin analog according to claim 18, wherein at least one of R.sub.3 and R.sub.4 is fluoro.

20. 2,2,16,16-Tetrafluoro-trans-4,5,13,14-tetradehydro-6.beta.-PGI.sub.1, a prostacyclin analog according to claim 19.

21. A prostacyclin analog according to claim 18, wherein at least one of R.sub.3 and R.sub.4 is methyl.

22. 2,2-Difluoro-16,16-dimethyl -trans-4,5,13,14-tetradehydro-6.beta.-PGI.sub.1, a prostacyclin analog according to claim 21.

23. A prostacyclin analog according to claim 18, wherein R.sub.3 and R.sub.4 are both hydrogen.

24. 2,2-Difluoro-trans-4,5,13,14-tetradehydro-6.beta.-PGI.sub.1, methyl ester, a prostacyclin analog according to claim 23.

25. 2,2-Difluoro-trans-4,5,13,14-tetradehydro-6.beta.-PGI.sub.1, tris(hydroxymethyl)amino methane salt, a prostacyclin analog according to claim 23.

26. 2,2-Difluoro-trans-4,5,13,14-tetradehydro-6.beta.-PGI.sub.1, adamantanamine salt, a prostacyclin analog according to claim 23.

27. 2,2-Difluoro-trans-4,5,13,14-tetradehydro-6.beta.-PGI.sub.1, a prostacyclin analog according to claim 23.